PEN vs DBVT vs NVAX vs ISRG vs SYK

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Novavax, Inc. (NVAX) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 4. 0x versus Penumbra, Inc. at 71. 3x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x — a reasonable growth-adjusted valuation.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +61. 7%, compared to -93. 7% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus NVAX's -89. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Penumbra, Inc.

(PEN) is the lower-risk stock at 0. 23β versus Novavax, Inc. 's 2. 22β — meaning NVAX is approximately 872% more volatile than PEN relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: Penumbra, Inc. grew EPS 1156% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, PEN leads at 18. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 1x forward P/E versus 65. 8x for Penumbra, Inc. — 46. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 134. 8% to $46. 33.

In this comparison, SYK (1.

2% yield) pays a dividend. PEN, DBVT, NVAX, ISRG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, NVAX: -89. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PEN is a mid-cap high-growth stock; DBVT is a mega-cap quality compounder stock; NVAX is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while PEN, DBVT, NVAX, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.